A non-invasive test for early detection of patients with aggressive prostate cancer.
A simple blood test that can identify patients with aggressive prostate cancer, without the need for biopsy
About Us
We are a team of researchers and clinicians who are currently working on improving diagnosis of aggressive prostate cancer.
Our research focuses on the role of extracellular vesicles (EVs) as drivers of aggressive prostate cancer. By detecting EVs in the blood we can gain valuable information about a patient’s cancer.
A non-invasive test can play a vital role in screening aggressive prostate cancer.
A non-invasive test can play a vital role in early detection of prostate cancer.
We have discovered that cancer-derived EVs can regulate the tumour microenvironment, making it more favourable for cancer growth and spread. We have developed a novel, non-invasive test that can detect cancer EVs in the blood and distinguish between aggressive and low-risk prostate cancers.
This test has the potential to improve the accuracy and reliability of prostate cancer detection and save men’s lives.
The Problem
New Prostate Cancer Cases
Prostate Cancer Deaths
New Cases (UK)
Prostate cancer is the second most common cancer and the fifth leading cause of cancer death among men worldwide, with an estimated 1,414,259 new cases and 375,304 deaths in 2020. In the UK, there are around 52,300 new cases of prostate cancer every year and around 12,000 deaths from prostate cancer.
Current diagnostic tests like PSA (Prostate-Specific Antigen) lack sufficient accuracy for early identification of patients at risk of aggressive disease, and accurate diagnosis often requires biopsy.
The only way to confirm prostate cancer is by taking a tissue sample from the prostate (a biopsy). This is an invasive and risky procedure that can cause infection, bleeding, pain, and other problems.
To confirm diagnosis of prostate cancer it is often necessary to take a tissue sample from the prostate (called a biopsy). This is an invasive and risky procedure that can cause infection, bleeding, pain and other problems.
Many men have biopsies that are not needed or show low-risk prostate cancer that does not need treatment. This wastes time, money, and resources and harms the quality of life of men with prostate cancer.
Therefore, there is a need for better non-invasive tests to enable early identification of patients with aggressive prostate cancer.
Why EVproDX?
EVproDX is a revolutionary screening test for prostate cancer that offers many advantages over the current methods. Unlike the PSA blood test, which is unreliable and can give false results, EVproDX can accurately detect cancer-derived extracellular vesicles (EVs) in the blood and distinguish between aggressive and low-risk prostate cancers.
Unlike the biopsy, which is invasive and risky, EVproDX is non-invasive and safe and does not require any special equipment or staff.
By limiting the need for invasive biopsy, we will improve the lives of patients with prostate cancer.
EVproDX is a rapid test that works with a blood sample that can provide results within a reasonable time, allowing patients who need treatment to be identified much sooner and have their treatment strategy tailored to their specific disease.
EVproDX can be repeated as often as needed, enabling patients to be monitored regularly and have any changes in their disease status reported promptly. This can improve the outcomes and well-being of patients with prostate cancer and reduce the costs and burden for the health care system.
EVproDX has promising results for aggressive prostate cancer screening. It is a non-invasive, accurate, and rapid test that can help men make informed decisions about their health and improve their quality of life.
Our Solution
Meet Our Team
Dr Jason Webber
Chief Executive Officer / Co-Founder
Swansea University
Dr Ffion Walters
Technology Transfer Officer
Swansea University
Prof Aled Clayton
Chief Scientific Officer / Co-founder
Cardiff University
Mr Gokul Vignesh Kanda Swamy
Clinical Lead
Swansea University
Dr Demi Pritchard
Research Lead
Swansea University
Register Your Interest
Share Your Insights
Do you want to help influence the future of early detection screening and to help fight prostate cancer?
Click the button below to take our survey and help us to take the fight to prostate cancer.
Contact Us
To register your interest and learn more about our test, please use the contact form below to get in touch with our team. We are particularly keen to hear from healthcare providers, clinicians, manufacturers of diagnostic tests/assays, prostate cancer patients (and their representatives), executive non-departmental public bodies, manufacturers of research tools/consumables, and scientific researchers.